Sign in
Taking people in United StatesNo phase

Nasal swab gene changes in restless legs syndrome with long-term dopamine agonist use

Looks at nasal swab gene activity in people with restless legs syndrome taking dopamine agonists.

Key facts

Who runs it
HBC Immunology Inc
Where
San Francisco, United StatesSee the site
Trial code
Registry title
Observe Change in Nasal Swab DRD2 Gene Expression in Restless Legs Syndrome (RLS) Patients on Prolonged Dopamine Agonist Treatment
Status
Recruiting
People taking part
50 people, planned
Started
1 Jul 2025
Planned end
27 Feb 2026
Type of study
Observational
Record updated
11 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with restless legs syndrome (RLS) who take a dopamine agonist drug. Nasal swabs will be collected to study gene activity.

Age
18 Years to 60 Years
Sex
All sexes can join.
Disease stage
A clinical diagnosis of restless legs syndrome (RLS).
Earlier treatment
People must be taking a dopamine agonist now, such as Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn) or Bromocriptine (Parlodel). One group has used it for less than 1 month, the other for 6 or more months.

Main reasons for not taking part

  • Using any medicine that might affect collecting nose lining cells with a nasal swab.

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Able to provide Informed Consent
  • Clinical diagnosis of Restless Legs Syndrome (RLS)
  • On-going Treatment with a dopamine agonist

Who cannot take part

  • Use of any medication that might affect nasal epithelial cell collection with a nasal swab

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 60 years old?

This trial is currently available in United States.

  • Alethios, Inc.San Francisco, United StatesContact: Zeenia Framroze, MATaking people

About the trial

What the trial wants to find out

The study aims to observe changes in dopaminergic genes expression in peripheral tissue upon prolonged dopamine agonist treatment on patients with Restless Legs Syndrome (RLS). Similar studies in Parkinson's disease have shown changes in alpha-synuclein expression, which might offer insights into the dopaminergic gene regulation seen in RLS. The dopamine agonist drugs to be included in this study are: Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine (Apokyn), Bromocriptine (Parlodel). Specifically, the study will collect nasal swabs of participants partitioned into two groups, those who have not used a dopamine agonist or been on a dopamine agonist for less than 1 month compared to those who have been on the medication for 6 or more months. This research could provide insight into changes in dopaminergic gene expression associated with Augmentation Syndrome (AS) which occurs after long term dopamine agonist treatment in RLS patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Gene Expression Changes on Extended Use of Dopamine Agonists in Restless Legs Syndrome (RLS)
Plain-language title
Nasal swab gene changes in restless legs syndrome with long-term dopamine agonist useGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06726785, who can take part
Record updated
11 September 2025